The Valley Desk

NCT04923893 · Interventional trial

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

Overall registry status Active not recruiting

Phase 3

Conditions Multiple Myeloma

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov